Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
1997-07-02
2002-10-01
Whisenant, Ethan C. (Department: 1655)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S024300, C435S006120
Reexamination Certificate
active
06458940
ABSTRACT:
BACKGROUND OF THE INVENTION
This invention relates to the human papillomavirus. More specifically, this invention relates to the inhibition, treatment, and diagnosis of human papillomavirus-associated lesions using synthetic oligonucleotides complementary to human papillomavirus nucleic acid.
Human papillomaviruses (HPV) comprise a group of at least 70 types, based on DNA sequence diversity as measured by liquid hybridization (Pfister et al. (1994)
Intervirol
. 37:143-149). These nonenveloped DNA viruses infect epithelial cells resulting in a range of lesions from benign skin and genital warts (condyloma acuminata) and epidermodysplasia verruciformis (EV) to respiratory or laryngeal papillomatosis and cervical carcinoma. Each virus type exhibits host specificity.
Several HPV types infect genital epithelia and represent the most prevalent etiologic agents of sexually transmitted viral disease. The genital HPV types can be further subdivided into “high-risk” types that are associated with the development of neoplasms, most commonly HPV-16 and HPV-18; and “low-risk” types that are rarely associated with malignancy, most commonly HPV-6 and HPV-11. The malignant types may integrate into the genome of the host cell, thereby eliminating the requirement for viral DNA replication gene products. In contrast, the benign types, most commonly HPV6 and HPV11, rely on viral proteins E1 and E2 for replication of the episomal genome.
Current treatment for HPV infection is extremely limited. There are at present no approved HPV-specific antiviral therapeutics. Management normally involves physical destruction of the wart by surgical, cryosurgical, chemical, or laser removal of infected tissue. Topical anti-metabolites such as 5-fluorouracil and podophyllum preparations have also been used. (Reichman in
Harrison's Principles of Internal Medicine
, 13th Ed. (Isselbacher et al., eds.) McGraw-Hill, Inc., NY (1993) pp. 801-803). However, reoccurrence after these procedures is common, and subsequent repetitive treatments progressively destroy healthy tissue. Interferon has so far been the only treatment with an antiviral mode of action, but its limited effectiveness restricts its use (Cowsert (1994)
Intervirol
. 37:226-230; Bornstein et al. (1993)
Obstetrics Gynecol. Sur
. 4504:252-260; Browder et al. (1992)
Ann. Pharmacother
. 26:42-45).
Two HPV types, HPV-6 and HPV-11 are commonly associated with laryngeal papillomas, or benign epithelial tumors of the larynx. Neonates may be infected with a genital papillomavirus at the time of passage through their mother's birth canal. By the age of two, papillomas will have developed, and infected juveniles will undergo multiple surgeries for removal of benign papillomas which may occlude the airway. To date there is no method of curing juvenile onset laryngeal papillomatosis. There is consequently a serious need for a specific antiviral agent to treat human papillomavirus infection.
New chemotherapeutic agents have been developed which are capable of modulating cellular and foreign gene expression (see, Zamecnik et al. (1978)
Proc. Natl. Acad. Sci
. (USA) 75:280-284). These agents, called antisense oligonucleotides, bind to target single-stranded nucleic acid molecules according to the Watson-Crick rule or to double stranded nucleic acids by the Hoogsteen rule of base pairing, and in doing so, disrupt the function of the target by one of several mechanisms: by preventing the binding of factors required for normal transcription, splicing, or translation; by triggering the enzymatic destruction of mRNA by RNase H, or by destroying the target via reactive groups attached directly to the antisense oligonucleotide.
Improved oligonucleotides have more recently been developed that have greater efficacy in inhibiting such viruses, pathogens and selective gene expression. Some of these oligonucleotides having modifications in their internucleotide linkages have been shown to be more effective than their unmodified counterparts. For example, Agrawal et al. (
Proc. Natl. Acad. Sci
. (USA) (1988) 85:7079-7083) teaches that oligonucleotide phosphorothioates and certain oligonucleotide phosphoramidates are more effective at inhibiting HIV-1 than conventional phosphodiester-linked oligodeoxynucleotides. Agrawal et al. (
Proc. Natl. Acad. Sci
. (USA) (1989) 86:7790-7794) discloses the advantage of oligonucleotide phosphorothioates in inhibiting HIV-1 in early and chronically infected cells.
In addition, chimeric oligonucleotides having more than one type of internucleotide linkage within the oligonucleotide have been developed. Pederson et al. (U.S. Pat. Nos. 5,149,797 and 5,220,007) discloses chimeric oligonucleotides having an oligonucleotide phosphodiester or oligonucleotide phosphorothioate core sequence flanked by nucleotide methylphosphonates or phosphoramidates. Agrawal et al. (WO 94/02498) discloses hybrid oligonucleotides having regions of deoxyribonucleotides and 2′-O-methyl- ribonucleotides.
A limited number of antisense oligonucleotides have been designed which inhibit the expression of HPV. For example, oligonucleotides specific for various regions of HPV E1 and E2 mRNA have been prepared (see, e.g., U.S. Pat. No. 5,364,758, WO 91/08313, WO 93/20095, and WO 95/04748).
A need still remains for the development of oligonucleotides that are capable of inhibiting the replication and expression of human papillomavirus whose uses are accompanied by a successful prognosis and low or no cellular toxicity.
SUMMARY OF THE INVENTION
The present invention provides synthetic oligonucleotides which are complementary to a nucleic acid sequence spanning the translational start site of human papillomavirus gene E1, and which includes at least 15 nucleotides.
Also provided are pharmaceutical compositions including such oligonucleotides, methods of treating, controlling, and preventing HPV infection, methods for detecting the presence of HPV in a sample, and kits for the detection of HPV in a sample.
REFERENCES:
patent: 5220007 (1993-06-01), Pederson et al.
patent: 5272250 (1993-12-01), Spielvogel et al.
patent: 5283171 (1994-02-01), Manos et al.
patent: 5527898 (1996-06-01), Bauer et al.
patent: 5550047 (1996-08-01), Mulder
patent: 5593840 (1997-01-01), Bhatnagar et al.
patent: 5639871 (1997-06-01), Bauer et al.
patent: 5652355 (1997-07-01), Metlev et al.
patent: 5795715 (1998-08-01), Livache et al.
patent: WO9108313 (1991-06-01), None
patent: WO9320095 (1993-10-01), None
patent: WO9528942 (1995-11-01), None
Evander et al., J. of Virological Methods 31 : 239-250 (1991).*
Agrawal et al., PNAS 86 : 7790-7794 (1989).*
Kempe et al., Nucleic Acids Research 10(21) : 6695-6714 (1982).*
Agrawal et al., PNAS 85 : 7079-7083 (1988).*
Storey et al., Nucleic Acids Research 19(15) : 4109-4114 (1991).*
Gregorie et al., J. of Clinical Microbiology 27(12) : 2660-2665 (1989).*
Sakamoto et al., Plant Molecular Biology 13 :611-614 (1989).*
Krawczyk et al., PNAS 89 :3761-3764 (1992).
Frank Bruce L.
Goodchild John
Greenfield Isobel M.
Kilkuskie Robert E.
Mills John S.
Hybridon, Inc.
McDonnell & Boehnen Hulbert & Berghoff
Whisenant Ethan C.
LandOfFree
HPV-specific oligonucleotides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with HPV-specific oligonucleotides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HPV-specific oligonucleotides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2995410